Aurora Financial Journal

Biogen Inc. (BIIB)

NASDAQ · Health care · Biological Products, (No Diagnostic Substances) · Financial statements, TTM figures and earnings dates

Biogen Inc. reported revenue of $9.94B over the trailing twelve months ended March 31, 2026, with net income of $1.37B. Annual financial statements are available for fiscal years 2007 to 2025, taken from the company's filings with the SEC. The next quarterly results release is estimated for October 29, 2026, based on the company's filing history.

Open interactive financials →

Key financials

USDTTM
2026-03-31
FY2025
2025-12-31
FY2024
2024-12-31
FY2023
2023-12-31
FY2022
2022-12-31
FY2021
2021-12-31
Income statement
Revenue$9.94B$9.89B$9.68B$9.84B$10.17B$10.98B
Gross profit–$7.49B$7.37B$7.30B$7.90B$8.87B
Operating income$1.62B$1.56B$1.91B$1.30B$3.59B$2.84B
Net income$1.37B$1.29B$1.63B$1.16B$3.05B$1.56B
Diluted EPS$9.30$8.79$11.18$7.97$20.87$10.40
Cash flow
Operating cash flow$2.59B$2.20B$2.88B$1.55B$1.38B$3.64B
Capital expenditure$167.9M$153.8M$153.7M$277.0M$240.3M$258.1M
Free cash flow$2.42B$2.05B$2.72B$1.27B$1.14B$3.38B
Balance sheet
Cash and equivalents$3.38B$3.01B$2.38B$1.05B$3.42B$2.26B
Total assets$29.48B$29.44B$28.05B$26.84B$24.55B$23.88B
Total liabilities$10.83B$11.18B$11.33B$12.05B$11.17B$12.92B
Total debt$6.29B$6.29B$6.30B$6.94B$6.28B$6.27B
Shareholders' equity$18.65B$18.26B$16.72B$14.80B$13.40B$10.90B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full BIIB page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open BIIB financials →